- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring a Recently Approved Therapy for Demodex
An expert ophthalmologist discusses a medication which targets enzymes in the Demodex mite, given over a six-week course.
EP: 1.Overview of Demodex Blepharitis
EP: 2.Pathophysiology of Demodex Blepharitis
EP: 3.Diagnosing Demodex Blepharitis in Clinical Practice
EP: 4.Differential Diagnosis: Key Features of Demodex Blepharitis
EP: 5.Risk Factors and Mental Health Impact of Demodex Blepharitis
EP: 6.Treatment of Demodex Blepharitis
EP: 7.Diagnosis and Prevalence of Demodex Blepharitis
EP: 8.Exploring a Recently Approved Therapy for Demodex
EP: 9.Payer Approval + Alternate Treatments for Demodex Blepharitis
EP: 10.Outlook on the Future of Demodex Blepharitis Treatment
EP: 11.Understanding Demodex Blepharitis Pathogenesis
EP: 12.Cost-Effective Medication Access in Demodex Blepharitis Treatment
EP: 13.Other Clinical Considerations in Demodex Blepharitis Treatment
This is a video synopsis/summary of an Insights involving Neda Shamie, MD.
There is a recently FDA-approved treatment for Demodex blepharitis called Xdemvy (lotilaner ophthalmic solution 0.25%). Xdemvy targets and paralyzes an enzyme only found in the Demodexmite, effectively eradicating the mite. It is used twice daily for 6 weeks to cover the full life cycle. Over the treatment course, thedrug shows an impressively effective response in not just controlling but eradicating Demodexinfestation. It is a fast, highly effective, and reliable treatment.
In studies and clinical practice, Xdemvy eyedrops have not had significant adverse effects. Most patients find it soothing to the ocular surface with no adverse reactions. About 10% of study patients described a burning sensation upon drop installation. Less than 2% developed chalazion or hordeolum while on treatment. Overallit is very safe, highly effective and welltolerated, with a 6-week, twice-daily course, which supports good compliance. Many patients report completing the full course, motivated to control their disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
